One injection. Sixty minutes. Muscle mitochondria in very old mice were producing energy like those of young animals.
That is the headline from a 2013 Aging Cell paper on SS-31, also known as elamipretide, a mitochondria-targeted peptide. Before anyone starts shopping for vials: this was a mouse study. Everything below describes what happened in rodents, and what has (and hasn't) happened in humans since.
What the Study Did
A team led by researchers at the University of Washington, with collaborators including SS-31's co-developer Hazel Szeto, tested a simple question. Can a drug rapidly reverse the mitochondrial decline seen in aged skeletal muscle?
The design was clean:
- Young mice: 5 months old.
- Old mice: 27 months old, which is very old for a mouse.
- Treatment: a single intraperitoneal injection of either saline or SS-31 at 3 mg/kg.
- Readout: one hour later, the team measured mitochondrial energetics in vivo. They combined optical spectroscopy with ³¹P magnetic resonance spectroscopy, which let them look at living muscle without removing it.
- Follow-up: a separate experiment used eight days of SS-31 treatment to test whole-animal endurance.
The in vivo measurement matters. Many mitochondrial findings come from isolated organelles in a dish. Here the muscle was working inside a living animal.
What It Found
The paper reports no effect sizes in its abstract, so we'll stick to the direction of the results, which were striking on their own.
In old mice, one hour after a single dose, SS-31 reversed age-related declines in:
- Resting mitochondrial ATP production
- Maximal mitochondrial ATP production
- P/O, a measure of how efficiently oxidative phosphorylation couples oxygen use to ATP synthesis
- PCr/ATP, an indicator of the muscle cell's energy state
The authors describe these as restored to young levels. In young muscle, SS-31 had no observable effect. That suggests it wasn't acting as a stimulant. It appeared to fix something specifically broken in aged tissue.
The redox data pointed the same way. Treated old muscle showed a more reduced glutathione redox status and lower mitochondrial H₂O₂ emission. In plain terms, the mitochondria looked less oxidatively stressed.
Two functional results followed:
- Fatigue resistance: aged muscle tested in situ one hour after treatment was more fatigue resistant.
- Endurance: after eight days of SS-31, whole-animal endurance capacity increased.
Why It Works (As Far As We Know)
SS-31 is a small cardiolipin-binding tetrapeptide. Cardiolipin is a lipid found in the inner mitochondrial membrane, where the electron transport chain operates. The working idea is that the peptide associates with cardiolipin and helps stabilize the machinery that produces ATP. That could explain why the effect showed up within an hour and why it appeared in old, but not young, muscle.
That explanation is a model, not a proven human mechanism. Treat it that way.
The Catch: This Is a Mouse Study
Here is the honest part.
- It's animal-only data. Mice are not small humans. Plenty of interventions that rejuvenate rodent tissue do little in people.
- The effect was acute. The headline result is a snapshot one hour after a single dose. It says nothing about how long benefits last or whether they accumulate.
- The endurance data is limited to eight days. That is a short window, and the abstract doesn't describe long-term outcomes.
- Intraperitoneal injection isn't a lifestyle protocol. It is a standard lab route, not a convenient human one.
- The authors are optimistic, not conclusive. They say SS-31 has "potential for translation into human use." Potential is not proof.
What We Know in Humans
Elamipretide (also called Bendavia) has had a long clinical journey, and it has been mixed.
The win: it received FDA accelerated approval for Barth syndrome in 2025. This is a rare genetic mitochondrial disease, and cardiolipin abnormalities are central to it. That is a strong fit with the drug's mechanism.
The disappointment: in primary mitochondrial myopathy, the MMPOWER-3 trial missed its primary endpoints. That is a real caution. A compelling mouse result and a sound mechanism didn't translate into a clean win in that patient population.
It's also worth noting that none of this establishes that elamipretide rejuvenates muscle in healthy older adults. That was the implication of the 2013 mouse paper, and it remains unproven.
How to Use It: Practical Takeaways
The biohacker-friendly answer is the least exciting one.
- Dose: there is no validated dose for healthy aging. The mouse dose was 3 mg/kg, but it should not be scaled to a human by simple arithmetic. Any human use belongs under a clinician's direction.
- Timing: in the study, effects were measured one hour after injection, and the endurance result came from an eight-day course. Those are experimental parameters, not a human schedule.
- Form: it is an injectable drug, not a supplement. There is no evidence in this paper for oral or topical versions.
- Who it's for: people with an approved indication, such as Barth syndrome, under medical supervision, or participants in clinical trials.
- Who should skip it: healthy people chasing an energy or longevity edge, anyone looking for a DIY anti-aging stack, and anyone who would source it without a prescription.
A Warning About Grey-Market "Research Peptides"
Anyone searching for SS-31 will quickly find vendors selling it as a "research peptide." Be skeptical. These products are unregulated. You can't count on purity, sterility, correct dosing, or even that the vial contains what the label says. Injecting an unverified product is a risk that a single promising mouse paper doesn't justify.
Bottom Line
This study is an elegant demonstration that, in aged mice, a mitochondria-targeted peptide can quickly shift muscle energetics toward a younger profile. It is a strong piece of preclinical science. It is not a human anti-aging protocol. Human results so far are real but narrow: approval in a rare disease, and a miss in a broader mitochondrial myopathy trial. The one-hour rejuvenation story is still a mouse story, and for now that is where it should stay.
